OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cannon on Suboptimal Efficacy Findings With Immunotherapy in Ovarian Cancer

September 7th 2023

Martin Cannon, PhD, discusses data seen with immune checkpoint inhibitors in patients with ovarian cancer and why these agents are not as effective in this population as they are in other cancer types.

Dr Burke on Treatment Paradigm Shifts in Relapsed DLBCL

September 7th 2023

John Burke, MD, discusses the evolution of the diffuse large B-cell lymphoma treatment paradigm.

Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations

September 6th 2023

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Dr Moore on the Design of a Phase 1/2 Study of Ubamatamab in Ovarian Cancer

September 6th 2023

Kathleen N. Moore, MD, MS, discusses the design of the ongoing, first-in-human, phase 1/2 study of the MUC16- and CD3-targeted bispecific antibody ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Li on the Impact of Immune-Related Adverse Effects in HCC

September 6th 2023

Daneng Li, MD, discusses how immune-related adverse effects can affect the treatment of patients with gastrointestinal cancer, specifically those with unresectable hepatocellular carcinoma.

Dr Hochster on the FRESCO-2 Trial in mCRC

September 6th 2023

Howard S. Hochster, MD, discusses data from the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care in metastatic colorectal cancer.

Dr McKean on the Rationale For Evaluating LAG-3 Inhibitors in Advanced Melanoma

September 6th 2023

Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination's efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.

Dr Wang on Switch Maintenance Therapy in Urothelial Carcinoma

September 6th 2023

Jue Wang, MD, professor, Department of Internal Medicine, member, Division of Hematology and Oncology, UT Southwestern Medical Center, discusses the benefits of switch maintenance therapy and individualized treatment strategies in patients with relapsed or refractory urothelial carcinoma.

Dr Hwang on Risk-Stratification Factors in Nonmetastatic Prostate Cancer

September 6th 2023

Clara Hwang, MD, discusses risk stratification methods used to assess the risk of metastatic disease in patients with nonmetastatic prostate cancer.

Dr Hwang on FDA-Approved Agents for nmCRPC

September 5th 2023

Clara Hwang, MD, highlights agents that the FDA has approved for use in patients with nonmetastatic castration-resistant prostate cancer, such as apalutamide, enzalutamide, and darolutamide.

Dr Vokes on Targeting HER3 in NSCLC

September 5th 2023

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer

September 5th 2023

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC

September 5th 2023

Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.

Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

September 5th 2023

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

September 1st 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

Dr Qin on Areas of Active and Future Investigation in NSCLC

September 1st 2023

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

September 1st 2023

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

September 1st 2023

Nirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.

Dr Tauro on the Rationale for Investigating ULK3 in Multiple Myeloma

September 1st 2023

Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.

Dr Islam on the Limited Use of Ibrutinib in CLL

September 1st 2023

Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.